GlassScriptPhysician profile
Keley J Booth
NPI 1558387696
$2,433.00
in general payments reported to CMS, 2019-2025
28 companies · $55.42 in 2025
The $55.42 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $741 · 2021: $308 · 2022: $465 · 2023: $168 · 2024: $124 · 2025: $55.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $302.13 | 2019-2023 | Ztlido |
| Collegium Pharmaceutical, INC. | $260.78 | 2019-2024 | Belbuca |
| Nevro Corp. | $247.50 | 2020 | |
| Nalu Medical, INC. | $198.71 | 2021-2024 | Nalu Neurostimulation System |
| Abbott Laboratories | $191.60 | 2019-2022 | |
| Pacira Therapeutics, INC. | $160.08 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.24 | 2020-2025 | Relistor, Xifaxan |
| Medtronic USA, INC. | $121.39 | 2019-2020 | |
| Organogenesis INC. | $93.29 | 2020-2021 | |
| Spr Therapeutics, INC | $87.53 | 2022 | |
| Biodelivery Sciences International, INC. | $85.98 | 2019-2021 | |
| Forte Bio-Pharma LLC | $62.98 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Horizon Therapeutics Plc | $61.15 | 2020-2022 | |
| Grt US Holding, INC. | $58.43 | 2020-2021 | |
| Medtronic, INC. | $44.82 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $42.01 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.43 | 2019 | |
| Bioventus LLC | $38.83 | 2019-2020 | |
| Sonex Health, INC. | $37.77 | 2021 | |
| Orexo US, INC. | $29.09 | 2019 | |
| Merck Sharp & Dohme LLC | $24.03 | 2020-2021 | |
| Stryker Corporation | $21.09 | 2022 | |
| Daiichi Sankyo INC. | $19.24 | 2019 | |
| Osiris Therapeutics INC. | $19.07 | 2019 | |
| Valinor Pharma, LLC | $17.07 | 2025 | Movantik |
| Lilly USA, LLC | $12.50 | 2019 | |
| Zyla Life Sciences, INC. | $11.26 | 2020 | |
| Pfizer INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keley Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.